----item----
version: 1
id: {4D32FBF6-8177-48C2-802C-045892822058}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/30/BIND and Pfizer extend timelines for preclinical collab
parent: {CB8312FA-59CF-4683-9123-7DB09EB8FEB8}
name: BIND and Pfizer extend timelines for preclinical collab
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 6aed09f1-36e6-4a7c-bee4-0d879d716693

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{1D288E18-BAFF-4498-B284-EF9BC8D32E30}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 55

BIND and Pfizer extend timelines for preclinical collab
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 55

BIND and Pfizer extend timelines for preclinical collab
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1388

<p> <p> Pfizer has opted to extend its discovery agreement with BIND Therapeutics for two preclinical oncology assets that use the biotech's nanomedicine platform to make Pfizer's own small molecules more targeted. Under the original agreement, which was inked in April 2013, BIND is eligible to receive another $190m in development, regulatory and commercial milestones should Pfizer opt into any of the programs. So far, the Cambridge, Mass.-based biotech has received $4m in upfront payments and $1m in preclinical milestones. Pfizer has until September 2015 to opt into the first development program and, under the new arrangement, until March 2016 to license the second program. &quot;The 2015 option target date on the first compound remains unchanged and this extension allows BIND and Pfizer an additional year to complete preclinical research evaluating the second program,&quot; said the biotech in a statement issued 06 April. Should the big pharma license either of the programs, Pfizer will be responsible for all development and commercial activities. An earlier oncology deal using BIND's nanomedicine technology was <a href="http://#http://www.scripintelligence.com/business/Amgen-unties-BIND-as-nanomedicine-collaboration-fails-352656" target="_new">abandoned by Amgen</a> in July 2014 when the collaboration failed to show promising results in early stages. </p> <p><p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 4

<p/>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 55

BIND and Pfizer extend timelines for preclinical collab
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150330T231503
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150330T231503
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150330T231503
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028335
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 55

BIND and Pfizer extend timelines for preclinical collab
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199600482
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357580
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042325Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

6aed09f1-36e6-4a7c-bee4-0d879d716693
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042325Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
